Latus has refocused its core activity from oncology R&D to identify, promote and facilitate the evaluation of treatments for COVID-19. This not for profit project orchestrated by Latus will assess the effectiveness of the existing drugs Camostat and Nafamostat to fight the virus.

Latus established a collaboration with Ono Pharmaceuticals for drug provision and secured £1M from LifeArc to support clinical evaluation. Latus will now be supported by Cancer Research UK to implement their trial strategy and test the effectiveness of both drugs in treating COVID-19 infected individuals with the essential support of the University of Edinburgh.

Image by Michael Longmire
Latus' SPIKE-1 trial: Camostat to be evaluated as a potential treatment for COVID-19
Latus' SPIKE-2 trial: Nafamostat to be trialled as the most potent antiviral drug candidate

Latus is delighted to announce its partnership  with Cancer Research UK, LifeArc & University of Edinburgh

Our Story

The science behind coronavirus' invasion of human cells

Image by Michael Longmire

SPIKE trials are designed to be

  • Because Camostat is an established drug

  • This means it is already cleared as safe to use, dramatically reducing lead times


© 2020 Latus Therapeutics